IFNG and primary cutaneous T-cell non-Hodgkin lymphoma: Recombinant IFNγ is a therapeutic agent that is similar to the endogenous IFNγ and exhibits immunoregulatory, antiviral, and antineoplastic activities.[28] It is FDA approved for the treatment of chronic granulomatous disease[29] and has also been used in atopic dermatitis[30] and cutaneous T cell lymphoma.[15] The contraindications and adverse effects are similar to those of IFNα.[29]